Open AccessThe Effect of Vitamin D treatment on COVID 19- Patients, an Inverted Propensity Score Weighting (IPSW), and Inverted Probability of Treatment Weighting (IPTW) Analyzed Study
Author(s) -
Jamal Wadi Al Ramahi,
Nour Hasan,
Amal Matar,
Ma’en Maher Al-Ali,
Lara Abdulhadi,
Dania Abu Kaf,
Waseem Saadeh,
Nour Hamdan,
Hassan Abu Khalaf,
Mohamed Gharaibeh,
Hanadi Hamadallah,
Ala’a Bader,
Mohammad Atout,
Sae’ed Moh. Mar’I,
Tamer Alhamed
Publication year - 2022
Publication title -
the international arabic journal of antimicrobial agents
Language(s) - English
Resource type - Journals
ISSN - 2174-9094
DOI - 10.3823/862
Subject(s) - medicine , propensity score matching , vitamin d and neurology , cohort , cumulative dose , covid-19 , retrospective cohort study , logistic regression , vitamin , cohort study , disease , infectious disease (medical specialty)
BackgroundVitamin D3 (1,25(OH)2 cholecalciferol) as a treatment for COVID 19 patients is being disputed, and a clear clinical benefit is not being confirmed.MethodsA retrospective evaluation for COVID-19 patients who were treated with various cumulative doses of vitamin D. Data was extracted from the COVID-19 database, it included patients admitted to three hospitals in Amman, Jordan. Characteristics of patients were tabulated and compared for all-cohort, and propensity score index (PSI) adjustment, The comparison was based on two vitamin D strata ((≤ 149,000 i.u. and > 150,000 i.u.). Logistic regression analysis was utilized to predict recovery, the need for oxygen, and all-cause mortality for all-cohort, IPSW, and IPTW patients, based on vitamin D cumulative doses during their hospital stay.Results 1131 all-cohort and 768 PSI-adjusted patients were recruited. Except for antibiotics and antivirals, all other characteristics were balanced (P = NS). There were 1017 patients on vitamin D, 847 received cumulative ≤ 149,000 i.u., and 170 patients received cumulative dose ≥ 150,000 i.u. (Range 1000 – 385000). It was demonstrated that escalating cumulative doses of vitamin D did not contribute to the assessed outcomes; all-cohort patients (OR = 1.000, 95% C.I. 1.000 to 1.000), IPSW (OR = 1.000, 95% C.I. 1.000 to 1.000), and the IPTW (OR = 1.000, 95% C.I. 1.000 to 1.000).Conclusion In our patients’ cohorts, we could not demonstrate a beneficial effect for vitamin D therapy in COVID-19 patients for recovery, the need for home oxygen, and all-cause mortality, by hospital discharge.